This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Jan 2012

Almac to Manufacture MGB Biopharma's Compound

Almac will manufacture MGB Biopharma's lead preclinical-stage candidate for the treatment of gram positive bacterial infections.

Almac’s Sciences Business Unit will manufacture the production of MGB Biopharma's lead gram positive antibacterial compound MGB-BP3.


MGB-BP3 is a DNA minor groove binder and is currently in preclinical development, with IND filing targeted for Q3 2012.


MGB Bio's chief executive officer, Dr. Miroslav Ravic, commented, “We were very quickly impressed with the approach taken by Almac and they have already shown an intuitive understanding of what it takes to support a small company like ours. We look forward to a continued successful relationship.”


Rick Dyer, vice president Operations at Almac, said, “Almac has a wealth of expertise in early phase clinical development and we ar

Related News